sumatriptan has been researched along with atropine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Feniuk, W; Humphrey, PP; Perren, MJ | 1 |
| Bartolini, A; Donaldson, S; Galeotti, N; Ghelardini, C; Nicolodi, M; Sicuteri, F | 1 |
| Coulie, B; Janssens, J; Peeters, T; Tack, J | 1 |
| Crema, A; Crema, F; De Ponti, F; Frigo, G; Moro, E; Nardelli, G | 1 |
| Camilleri, M; Coulie, BJ; Farrugia, G; Locke, GR; Meulemans, A; Schuurkes, JA; Szurszewski, JH; Xue, L | 1 |
1 review(s) available for sumatriptan and atropine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for sumatriptan and atropine
| Article | Year |
|---|---|
Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans.
Topics: Anti-Bacterial Agents; Atropine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythromycin; Gastrointestinal Motility; Humans; Manometry; Muscarinic Antagonists; Myoelectric Complex, Migrating; Pyloric Antrum; Serotonin Antagonists; Sumatriptan | 1998 |
17 other study(ies) available for sumatriptan and atropine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetized dogs are not of the 5-HT1A or 5-HT1D subtype.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Anesthesia; Animals; Atropine; Carotid Arteries; Dogs; Ganglionic Blockers; In Vitro Techniques; Indoles; Ketanserin; Methiothepin; Muscle, Smooth, Vascular; Pyrilamine; Receptors, Serotonin; Saphenous Vein; Spiperone; Sulfonamides; Sumatriptan; Tetrahydronaphthalenes; Vasoconstriction; Vasoconstrictor Agents | 1991 |
Involvement of central cholinergic system in antinociception induced by sumatriptan in mouse.
Topics: Analgesics; Animals; Atropine; Dose-Response Relationship, Drug; GABA Antagonists; Hemicholinium 3; Male; Mice; Organophosphorus Compounds; Pain Threshold; Piperazines; Receptors, Cholinergic; Sumatriptan | 1997 |
Role of 5-HT1B/D receptors in canine gastric accommodation: effect of sumatriptan and 5-HT1B/D receptor antagonists.
Topics: Animals; Atropine; Benzamides; Bethanechol; Biphenyl Compounds; Dogs; Enzyme Inhibitors; Female; Gastric Emptying; NG-Nitroarginine Methyl Ester; Oxadiazoles; Parasympatholytics; Parasympathomimetics; Piperazines; Pressure; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Stomach; Sumatriptan; Vagus Nerve | 2003 |
Effect of modulation of serotonergic, cholinergic, and nitrergic pathways on murine fundic size and compliance measured by ultrasonomicrometry.
Topics: Animals; Atropine; Bethanechol; Buspirone; Gastric Fundus; Male; Mice; Muscle Contraction; Muscle, Smooth; Nitroglycerin; Reproducibility of Results; Serous Membrane; Signal Transduction; Sumatriptan; Ultrasonography | 2006 |